Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Levosert 20 microgram/24 hours Intrauterine Delivery System

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Levonorgestrel may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Levonorgestrel

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Levosert is an intrauterine delivery system (IUS) for insertion in the womb (uterus), where it slowly releases the hormone levonorgestrel. It is used for: Contraception Levosert is an effective, long-term and non-permanent (reversible) method of contraception. Levosert prevents pregnancy by thinning the lining of your womb (uterus), by making the normal mucus in the opening of the womb (cervical canal) thicker, so that the sperm cannot get through to fertilise the egg and by preventing the release of eggs (ovulation) in some women. Furthermore, the presence of the Tshaped frame causes local effects on the lining of the womb. Levosert should be removed or replaced no later than 8 years after intersion when used for contraception. Treating heavy menstrual bleeding Levosert is also useful for reducing menstrual blood flow, so it can be used if you suffer from heavy menstrual bleeding (periods). This is called menorrhagia. The hormone in Levosert acts by thinning the lining of your uterus, so that there is less bleeding every month. Levosert should be removed or replaced no later than 8 years after insertion, or earlier if heavy or bothersome menstrual bleeding returns. Children and adolescents Levosert is not indicated for use before the first menstrual bleeding (menarche). 2.

What you need to know before you take it

e Levosert

Do not use Levosert if you are pregnant or suspect that you may be pregnant; if you have or have had pelvic inflammatory disease; if you have an unusual or unpleasant vaginal discharge, or vaginal itching, as this may indicate an infection; if you have or have had inflammation of the lining of your womb following delivery of your baby; 1

–

if you have or have had an infection of the womb after delivery or after abortion during the past 3 months; if you have or have had inflammation of the cervix (neck of your womb); if you have or have had an abnormal smear test (changes in the cervix); if you have or have had liver problems; if you have liver tumour; if you have an abnormal womb, including uterine fibroids, especially those that distort the uterine cavity; if you have undiagnosed vaginal bleeding; if you have any condition which makes you susceptible to infections. A doctor will have told you if you have this. if you have or have had hormone dependent cancer, such as breast cancer; if you have or have had any type of cancer or suspected cancer including blood (leukaemia), uterine and cervical cancer, unless in remission; if you have or have had trophoblastic disease. A doctor will have told you if you have this. if you are allergic (hypersensitive) to levonorgestrel or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions Before you have Levosert fitted, your doctor or nurse will carry out some tests to make sure that Levosert is suitable for you to use. This will include a pelvic examination and may also include other examinations such as a breast examination, if your doctor or nurse feels this is appropriate. Genital infections will need to be successfully treated before you can have Levosert fitted. If you have epilepsy, tell the doctor or nurse fitting Levosert because, although rare, a fit can occur during insertion. Some women might feel faint after the procedure. This is normal and your doctor or nurse will tell you to rest for a while. Levosert may not be suitable for all women. Levosert, like other hormonal contraceptives, does not protect against HIV infection (AIDS) or any other sexually transmitted disease (e.g. chlamydia, genital herpes, genital warts, gonorrhoea, hepatitis B and syphilis). You will need condoms to protect yourself from these diseases. Levosert should not be used as a post-coital contraceptive (after unprotected sexual intercourse). Talk to your doctor before using Levosert if you have or develop migraine, dizziness, blurred vision, unusually bad headaches or if you have headaches more often than before; if you have yellowing of the skin or whites of the eyes (jaundice); if you are diabetic (too high blood glucose level), have high blood pressure or abnormal blood lipid levels; if you have had cancer affecting your blood (including leukaemia) which is now in remission; if you are on long-term steroid therapy; if you have ever had an ectopic pregnancy (development of the foetus outside the womb) or a history of ovarian cysts; if you have had or have severe arterial disease, such as heart attack, or stroke, or if you have any heart problems; if you have a history of blood clots (thrombosis); if you are taking any other medicines as some medicines may stop Levosert from working properly; if you have irregular bleedings; if you have fits (epilepsy). Your doctor will decide if you can use Levosert if you have or have had some of the above conditions. 2

You must also tell your doctor if any of these conditions occur for the first time whilst you have Levosert in place. Blood clots You must see a doctor or nurse as soon as possible if you develop painful swelling in your leg, sudden chest pain or difficulty in breathing as these may be a sign of a blood clot. It is important that any blood clots are treated promptly. Ectopic pregnancy The following signs and symptoms could mean that you may have an extrauterine pregnancy (pregnancy outside the uterus) and you should see your healthcare professional immediately (see also section "Pregnancy, breast-feeding and fertility"): Your menstrual periods have stopped and then you start having persistent bleeding or pain. You have pain in your lower abdomen that is severe or persistent. You have normal signs of pregnancy, but you also have bleeding and feel dizzy. You have a positive pregnancy test. Expulsion The muscular contractions of the womb during menstruation may sometimes push the IUS out of place or expel it. This is more likely to occur if you are overweight at the time of IUS insertion or have a history of heavy periods. If the IUS is out of place, it may not work as intended and therefore, the risk of pregnancy is increased. If the IUS is expelled, you are not protected against pregnancy anymore. Possible symptoms of an expulsion are pain and abnormal bleeding but Levosert may also come out without you noticing. As Levosert decreases menstrual flow, increase of menstrual flow may be indicative of an expulsion. It is recommended that you check for the threads with your finger, for example while having a shower. See also section 3 "How to use Levosert – How can I tell whether the system is in place?". Do not pull the threads because you may accidentally pull out Levosert. If you have signs indicative of an expulsion or you cannot feel the threads, you should use another contraceptive (such as condoms), and consult your healthcare professional. Infections You must also see a doctor without delay if you develop persistent lower abdominal pain, fever, pain during sexual intercourse or abnormal bleeding. If you get severe pain or fever shortly after Levosert has been inserted, you may have a severe infection which must be treated immediately. Psychiatric disorders Some women using hormonal contraceptives including Levosert have reported depression or depressed mood. Depression can be serious and may sometimes lead to suicidal thoughts. If you experience mood changes and depressive symptoms contact your doctor for further medical advice as soon as possible. Breast cancer Women who take the pill (contraceptive) have a slightly increased risk of breast cancer. This returns to the age-appropriate basic risk within 10 years of stopping the pill. Some scientific studies have suggested a slightly increased risk of breast cancer with use of levonorgestrel IUS like Levosert, while other studies have not suggested an increased risk. Talk to your doctor if you have any concerns. Levosert and smoking Women are advised to give up smoking. Smoking increases the risk of developing a heart attack, stroke, or blood clot. Use of tampons and menstrual cups Use of sanitary pads is recommended. If tampons or menstrual cups are used, you should change them with care so as not to pull the threads of Levosert. 3

Other medicines and Levosert The effect of hormonal contraceptives such as Levosert may be reduced by medicines that increase the amounts of enzymes made by the liver. Please tell your doctor if you are taking:

  • phenobarbital, phenytoin or carbamazepine (to treat epilepsy);
  • fluconazole, griseofulvin (an antifungal);
  • rifampicin or rifabutin (antibiotics);
  • nevirapine or efavirenz (for HIV). Tell your doctor if you are taking, have recently taken or might take any other medicines. Levosert should not be taken simultaneously with another hormonal contraceptive method. Pregnancy, breast-feeding and fertility Levosert must not be used during pregnancy or if you may suspect that you are pregnant. Can I become pregnant whilst using Levosert? It is very rare for women to become pregnant with Levosert in place. Missing a period may not mean that you are pregnant. Some women may not have periods whilst using the system. If you have not had a period for 6 weeks then consider having a pregnancy test. If this is negative there is no need to carry out another test, unless you have other signs of pregnancy, e.g. sickness, tiredness or breast tenderness. If you become pregnant with Levosert in place, you should see your healthcare professional immediately to have Levosert removed. The removal may cause a miscarriage. However, if Levosert is left in place during pregnancy, not only the risk of having a miscarriage is higher, but also the risk of preterm labour. If Levosert cannot be removed, talk with your healthcare professional about the benefits and risks of continuing the pregnancy. If the pregnancy is continued, you will be closely monitored during your pregnancy and you should contact your doctor right away if you experience stomach cramps, pain in your stomach or fever. Levosert contains a hormone, called levonorgestrel, and there have been isolated reports of effects on the genitalia of female babies if exposed to levonorgestrel intra-uterine devices while in the womb. What if I want a baby? If you want a baby, ask your doctor to remove Levosert. Your usual level of fertility will return very quickly after the system is removed. Can I breast feed while using Levosert? Very small amounts of the hormone in Levosert are found in breast milk. A risk to the newborns/infants is not expected. Breast-feeding can be continued during use of Levosert. Driving and using machines There are no known effects on the ability to drive or use machines. Levosert contains barium sulphate The T-frame of Levosert contains barium sulphate so that it can be seen on X-rays. 3.

How to take it

Levosert

Only a doctor or specially trained nurse can fit the system (see special instructions for insertion in the package). They will explain the fitting procedure and any risks associated with its usage. You will then be examined by your doctor or nurse before Levosert is fitted. If you have any concerns over its usage you should discuss it with them. During insertion procedure, a slight discomfort might be encountered. Inform your doctor about any pain you feel. 4

Starting to use Levosert  Before Levosert is inserted, it needs to be ensured that you are not pregnant.  You should have Levosert inserted within 7 days from the start of your menstrual period. When Levosert is inserted on these days, Levosert works right away and will prevent you getting pregnant.  If you cannot have Levosert inserted 7 days from the start of your menstrual period or if your menstrual period comes at unpredictable times, then Levosert can be inserted on any other day. In this case, you must not have had sexual intercourse without contraception since your last menstrual period, and you should have a negative pregnancy test before insertion. Also, Levosert may not reliably prevent pregnancy right away. Therefore, you should use a barrier method of contraception (such as condoms) or abstain from vaginal intercourse during the first 7 days after Levosert is inserted.  Levosert is not suitable for use as an emergency contraceptive (postcoital contraceptive). Starting to use Levosert after giving birth  Levosert can be inserted after giving birth once the uterus has returned to normal size, but not earlier than 6 weeks after delivery (see section 4 "Possible side effects – Perforation").  See also "Starting to use Levosert" above for what else you need to know about the timing of insertion. Starting to use Levosert after an abortion Levosert can be inserted immediately after an abortion, if the pregnancy was less than 3 months along provided that there are no genital infections. Levosert will then work right away. Replacing Levosert Levosert can be replaced by a new Levosert at any time of your menstrual cycle. Levosert will then work right away. Changing from another contraceptive method (such as combined hormonal contraceptives, implant)  Levosert can be inserted immediately if it is reasonably certain that you are not pregnant.  If it has been more than 7 days since your menstrual bleeding began, you should abstain from vaginal intercourse or use additional contraceptive protection for the next 7 days. Placement of Levosert Examination by your healthcare professional before placement may include:  a cervical smear test (Pap smear)  examination of the breasts  other tests, e.g. for infections, including sexually transmitted diseases, pregnancy test, as necessary. Your healthcare professional will also do a gynaecological examination to determine the position and size of the womb. After a gynaecological examination  An instrument called a speculum is placed into the vagina, and the cervix may be cleansed with an antiseptic solution. Levosert is then placed into the womb using a thin, flexible plastic tube (the placement tube). Local anaesthesia may be applied to the cervix prior to placement.  Some women feel dizzy or faint during placement or after Levosert is placed or removed.  You may experience some pain and bleeding during or just after placement. After placement of Levosert you should receive a patient reminder card from your doctor for followup examinations. Bring this with you to every scheduled appointment. How quickly should Levosert work? Contraception

5

If Levosert is inserted into your womb either during your period or within 7 days from the beginning of your period or you have a device and it is time to replace it with a new one or if you just had an abortion, you are protected from pregnancy as soon as the system is fitted. Heavy menstrual bleeding Levosert usually results in lighter periods after 3 to 6 months of treatment. How will Levosert affect my periods? Many women have spotting (a small amount of blood loss) for the first 3-6 months after the system is fitted. Others will have prolonged or heavy bleeding. You may have an increase in bleeding however, usually in the first 2 to 3 months, before a reduction in blood loss is achieved. Overall, you are likely to have fewer days of bleeding in each month and you might eventually have no periods at all. This is due to the effect of the hormone (levonorgestrel) on the lining of the womb. If a remarkable reduction in blood loss is not achieved after 3 to 6 months, other treatments should be considered. If you develop any new vaginal bleeding or experience a change in bleeding patterns after using Levosert for some time, consult your doctor or nurse as this could be a sign that Levosert has been expelled or is no longer working well enough for you. How often should I have the system checked? You should have your Levosert checked 4 to 6 weeks after placement, and thereafter regularly, at least once a year until it is removed. Your doctor may determine how often and what kinds of check-ups are required in your particular case. Bring the patient reminder card you have received from your doctor to every scheduled appointment. In addition, you should contact your doctor if any of the symptoms described in section 2 "Warnings and precautions" occur. How can I tell whether the system is in place? After each menstrual period, you can feel for the two thin threads attached to the lower end of the system. Your doctor will show you how to do this. Do not pull the threads because you may accidentally pull it out. If you cannot feel the threads, contact your doctor or nurse as soon as possible and in the meantime avoid intercourse or use a barrier contraceptive (such as condoms). The threads may have simply drawn up into the womb or cervical canal. If the threads still cannot be found by your doctor or nurse, they may have broken off, or Levosert may have come out by itself, or in rare cases it may have perforated the wall of your womb (uterine perforation, see section 4). You should also go to your doctor if you can feel the lower end of the device itself or you or your partner feel pain or discomfort during sexual intercourse. What happens if the system comes out by itself? If the system comes out either completely or partially, you may not be protected against pregnancy. It is rare but possible for this to happen without you noticing during your menstrual period. An unusual increase in the amount of bleeding during your period might be a sign that this has happened. Tell your doctor or healthcare provider if there are any unexpected changes in your bleeding pattern. Removal of Levosert Levosert should be removed or exchanged after 8 years of use, or earlier if heavy or bothersome menstrual bleeding returns. Your doctor can easily remove the system at any time, after which pregnancy is possible. Some women feel dizzy or faint during or after Levosert is removed. You may experience some pain and bleeding during removal of Levosert. Continuation of contraception after removal If pregnancy is not desired, Levosert should not be removed after the seventh day of the menstrual cycle (monthly period) unless you use other methods of contraception (e.g. condoms) for at least 7 days before the IUS removal. 6

If you have irregular periods (menses) or no periods, you should use a barrier method of contraception for 7 days before removal. A new Levosert can also be placed immediately after removal, in which case no additional protection is needed. If you do not wish to continue using the same method, ask your doctor for advice about other reliable contraceptive methods. If you have any further questions on the use of this medicine, ask your doctor. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. With Levosert, side effects are most common during the first months after the system is fitted and decrease as time goes on. If you experience any of the following serious side effects please contact your doctor or nurse immediately: Severe pain or fever developing shortly after insertion may mean that you have a severe infection which must be treated immediately. In rare cases very severe infection (sepsis) can occur. –

Severe pain and continued bleeding as this might be a sign of damage or tear in the wall of the womb (perforation). Perforation is uncommon, but occurs most often during the fitting of the Levosert, although the perforation may not be detected until sometime later. A Levosert which has become lodged outside the cavity of the womb is not effective in preventing pregnancy and must be removed as soon as possible; very rarely this may require surgery. The risk of perforation is low, but is increased in breastfeeding women and in women who have had a baby up to 36 weeks before insertion and may be increased in women with the uterus fixed and leaning backwards (fixed retroverted uterus). If you suspect you may have experienced a perforation, seek prompt advice from a healthcare provider and remind them that you have Levosert inserted, especially if they were not the person who inserted it. Possible signs and symptoms of perforation may include: severe pain (like menstrual cramps) or more pain than expected heavy bleeding (after insertion) pain or bleeding which continues for more than a few weeks sudden changes in your periods pain during sex you can no longer feel the Levosert threads (see "How can I tell whether the system is in place?" in section 3).

–

Lower abdominal pain especially if you also have a fever or have missed a period or have unexpected bleeding, as this might be a sign of ectopic pregnancy (development of the foetus outside the womb). The absolute risk of ectopic pregnancy in Levosert users is low. However, when a woman becomes pregnant with Levosert in place, the relative likelihood of ectopic pregnancy is increased.

–

Lower abdominal pain or experience painful or difficult sex as this might be a sign of ovarian cysts or pelvic inflammatory disease. This is important as pelvic infections can reduce your chances of having a baby and can increase the risk of ectopic pregnancy.

Very common (may affect more than 1 in 10 women): absent, light or infrequent menstrual periods (see "How will Levosert affect my periods?" in section 3); vaginal bleeding including spotting; ovarian cysts; 7

–

bacterial or fungal infections of the vagina and the outer genitalia (vulva); spots (acne); pain or bleeding during the insertion.

Common (may affect up to 1 in 10 women): depression, nervousness or other mood changes; reduced sex drive; headache; migraine; feeling faint (presyncope); dizziness; –

abdominal, pelvic or back pain; abdominal discomfort; feeling sick (nausea); bloated abdomen; vomiting; painful periods;. inflammation of the vagina and the outer genitalia (vulva); increased vaginal discharge; tender, painful breasts; painful sexual intercourse; spasm of the womb; Levosert coming out by itself; weight gain.

Uncommon (may affect up to 1 in 100 women): fainting; eczema; uterine perforation; ectopic pregnancy; genital infections that may cause: vaginal itching; pain on passing urine; or lower abdominal (tummy) pain from inflammation of the womb, ovaries or Fallopian tubes; inflammation of the neck of the womb (cervicitis); inflammation of the inner lining of the womb (endometritis); bloating or swelling of your legs or ankles; increased growth of hair on the face and body; hair loss; itchy skin (pruritus); skin discolouration or increased skin pigment, especially on the face (chloasma). Rare (may affect up to 1 in 1,000 women): allergic reaction (symptoms may include rash, itching or rapid swelling of the face, mouth, tongue and/or throat). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist, nurse or other healthcare professional. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. For long-acting products like Levosert, please report information of when Levosert was inserted and removed, as applicable. 5.

How to store it

Levosert 8

Store in the original package. Keep the pouch in the outer carton in order to protect from light. Keep the pack tightly closed. Do not open the Levosert pack. Only your doctor or healthcare provider should do this. Keep this medicine out of the sight and reach of children. Do not use the system after the expiry date which is stated on the pouch and the outer carton after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Levosert contains –

Levosert contains 52 mg of levonorgestrel, the active substance. The hormone is contained within a substance called polydimethylsiloxane. This is surrounded by a membrane (skin) also made of polydimethylsiloxane.

What Levosert looks like and contents of the pack –

Levosert consists of a small T-shaped frame made from a plastic called polyethylene. This structure provides a device for releasing the hormone gradually into the uterus (womb). There are two fine threads, made of polypropylene and copper phtalocyanine blue, attached to the bottom of the frame. These allow easy removal and allow you or your doctor to check that the device is in place.

Levosert IUS with the inserter device is individually packed into a peel pouch that is made up of 2 sheets: thermoformed pouch (polyester) package with a peelable lid. Each pack contains one Levosert in peel pouch that is single packed into one separated folding carton with the patient informaton leaflet and the patient reminder card. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Gedeon Richter Plc. Gyömrői út 19-21. 1103 Budapest Hungary Manufacturer Odyssea Pharma SRL Rue du Travail 16 4460 Grâce Hollogne Belgium Gedeon Richter Plc. Gyömrői út 19-21. 1103 Budapest Hungary

9

This leaflet was last revised in March 2026. _________________________________________________________________________________ The following information is intended for healthcare professionals only See special instruction leaflet enclosed in the pack.

10

Instructions for use and handling Levosert 20 micrograms/24 hours Intrauterine Delivery System levonorgestrel Prescriber Check List Ask yourself the following questions before prescribing/inserting Levosert: 

Have I checked that the patient's needs meet the indications of contraception or heavy menstrual bleeding and for duration of use of up to eight years?

Have I completed the patient card included in the pack and given this to the patient as a reminder (any insertions of more than eight years in duration should be reported as off label use)? Insertion instructionsPlease read the following instructions for use carefully as there may be some difference in the type of inserter device compared with other IUDs you have used previously:

11

To be inserted by a healthcare professional using aseptic technique. It is recommended that Levosert should only be inserted by healthcare professionals who are experienced in IUS insertions and/or have undergone sufficient training on the Levosert insertion procedure and have read carefully these instructions before Levosert insertion. Levosert is supplied in a sterile pack which should not be opened until required for insertion. Do not resterilise. For single use only. The exposed product should be handled with aseptic precautions. If the seal of the sterile package is broken, the product should be discarded (see Summary of Product Characteristics section 6.6 for disposal instructions). Do not use if the inner package is damaged or open. Do not insert after the expiry date which is stated on the carton and the pouch after EXP. The expiry date refers to the last day of that month. For timing of insertion, please see Summary of Product Characteristics section 4.2. Levosert is supplied with a patient reminder card in the outer carton. Complete the patient reminder card and give it to the patient, after insertion. Preparation for insertion  Examine the patient to rule out contraindications for the insertion of Levosert (see Summary of Product Characteristics section 4.3 and section 4.4 under Medical examination/consultation).  Insert a speculum, visualize the cervix, and then thoroughly cleanse the cervix and vagina with a suitable antiseptic solution.  Employ an assistant as necessary.  Grasp the anterior lip of the cervix with a tenaculum or other forceps to stabilize the uterus. If the uterus is retroverted, it may be more appropriate to grasp the posterior lip of the cervix. Gentle traction on the forceps can be applied to straighten the cervical canal. The forceps should remain in position and gentle counter traction on the cervix should be maintained throughout the insertion procedure.  Advance a uterine sound through the cervical canal to the fundus to measure the depth. If uterine depth is < 5.5 cm discontinue the procedure. Confirm the direction of the uterine cavity and to exclude any evidence of intrauterine abnormalities (e.g., septum, submucous fibroids) or a previously inserted intrauterine contraceptive which has not been removed. If difficulty is encountered, consider dilatation of the canal. If cervical dilatation is required, consider using analgesics and/or a paracervical block. For timing of insertion, please see Summary of Product Charasteristics section 4.2. Levosert is supplied with a patient reminder card in the outer carton. Complete the patient reminder card and give it to the patient after insertion. Description Figure 1

12

13

Getting ready for insertion Figure 2

Figure 3

Introduce the plunger and the IUS in the insertion tube Partly open the pouch (about 1/3 from the bottom) and introduce the plunger in the insertion tube. Extricate the threads from the flange. Pull the thread to introduce the IUS into the tube. The arms of the IUS must stay in a horizontal plane, parallel to the flat side of the flange.

Figure 4

Position the lower edge of the flange at the sounded value Position the blue flange so as the lower edge of the flange indicates the value found by hysterometry. The flat sides of the flange must always remain parallel to the arms. This will allow the arms to open correctly in the uterine cavity.

14

Figure 5 Adjust the position of the IUS in the insertion tube Hold the plunger firmly while pulling the thread and moving the tube to adjust the position of the IUS. The knobs of the lateral arms must be closely opposed to each other, slightly above the upper extremity of the insertion tube (see zoom 1) and the distal edge of the tube must be aligned with the first indent of the plunger (see zoom 2). If the tube is not aligned with the first indent of the plunger you must pull the thread more firmly.

Insertion Figure 6 Introduce the device in the cervical canal until the blue flange is in contact with the cervix Take the whole device out of the pouch, by holding firmly the plunger and tube together in the correctly adjusted position. Introduce the assembly into the cervical canal until the blue flange is in contact with the cervix.

15

Figure 7 Release the arms of the intrauterine device Hold the plunger, release the thread and pull the insertion tube down until its lower extremity reaches the second indent of the plunger.

Figure 8 Push the IUS against the fundus To position the IUS in the uterine cavity, push the insertion tube simultaneously with the plunger, until the blue flange is again in contact with the cervix. Levosert is then correctly placed in the uterine cavity.

16

Figure 9 Release the IUS from the tube into the uterine cavity Without moving the plunger, pull the insertion tube down to the ring of the plunger. A slight resistance marks the passage of the bulge of the plunger. Nevertheless pull down the tube to the ring of the plunger. Levosert is then released completely from the insertion tube.

Figure 10

Remove sequentially the inserter components and cut the threads Remove sequentially, first the plunger, then the insertion tube. Cut the threads at around 3 cm from the cervix.

Insertion of Levosert is now complete. Important information to consider during or after insertion: If you suspect the IUS is not in the correct position: Check insertion with an ultrasound or other appropriate radiologic test.

17

–

If incorrect insertion is suspected, remove Levosert. Do not reinsert the same Levosert IUS after removal.

18

IMPORTANT! In case of difficult insertion and/or exceptional pain or bleeding during or after insertion, the possibility of perforation should be considered and appropriate steps should be taken, such as physical examination and ultrasound. If necessary remove the system and insert a new, sterile system. After insertion, women should be re-examined after 4 to 6 weeks to check the threads and ensure that the device is in the correct position. Physical examination alone (including checking of threads) may not be sufficient to exclude partial perforation. Please report any case of uterine perforation or insertion difficulties via Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Removal/ replacement Levosert is removed by gently pulling on the threads with forceps. If the threads are not visible and the system is found to be in the uterine cavity on ultrasound exam, it may be removed using the narrow forceps. This may require dilatation of the cervical canal or surgical intervention. After removal of Levosert, the system should be examined to ensure it is intact. During difficult removals, single cases have been reported of the hormone cylinder sliding over the horizontal arms and hiding them together inside the cylinder. This situation does not require further intervention once completeness of the IUS has been ascertained. The knobs of the horizontal arms usually prevent complete detachment of the cylinder from the T-body.

19

Frequently asked questions about Levosert 20 microgram/24 hours Intrauterine Delivery System

What is the active substance in Levosert 20 microgram/24 hours Intrauterine Delivery System?

The active substance in Levosert 20 microgram/24 hours Intrauterine Delivery System is levonorgestrel.

Are there equivalent medicines to Levosert 20 microgram/24 hours Intrauterine Delivery System?

Medicines with the same active substance, strength and form include: Benilexa One Handed 20 micrograms/24 hours Intrauterine Delivery System, Mirena 20 micrograms/24 hours intrauterine delivery system. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Levosert 20 microgram/24 hours Intrauterine Delivery System, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Levosert 20 microgram/24 hours Intrauterine Delivery System without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Levonorgestrel (25 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Contraception.

Treatment of heavy menstrual bleeding. Levosert may be particularly useful in women with heavy menstrual bleeding requiring (reversible) contraception.

4.2. Posology and method of administration

Posology

Levosert is inserted into the uterine cavity and is effective for eight years in the indication contraception and has a demonstrated efficacy for 3 years for the indication heavy menstrual bleeding. Therefore, Levosert should be removed or exchanged after 8 years of use, or earlier if heavy or bothersome menstrual bleeding returns.

Insertion

It is strongly recommended that Levosert should only be inserted by healthcare professionals who are experienced in IUS insertions and/or have undergone training for the Levosert insertion procedure.

Before insertion, the patient should be carefully examined in order to detect any contraindication to IUS insertion. Exclude pregnancy before insertion. Consider the possibility of ovulation and conception before using this product. Levosert is not suitable for use as a post-coital contraceptive (see section 4.3 and section 4.4 under Medical examination).

Contraception and heavy menstrual bleeding

Table 1. When to insert Levosert in women of fertile age

Starting Levosert

- Levosert should be inserted into the uterine cavity within 7 days of the onset of menstruation. In this case Levosert provides contraceptive protection upon insertion and no back-up contraception is needed.

- If insertion within 7 days of the onset of menstruation is not possible or the woman does not experience regular menses, Levosert may be inserted at any time during the menstrual cycle provided that the healthcare professional can reliably exclude the possibility of prior conception. However, in this case immediate contraceptive protection upon insertion is not reliably ensured. Therefore, a barrier method of contraception should be used or the patient should abstain from vaginal intercourse for the next 7 days to prevent pregnancy.

Postpartum insertion

In addition to the instructions above (Starting Levosert):

Postpartum insertions should be postponed until the uterus is fully involuted, however should not be performed earlier than 6 weeks after delivery. If involution is substantially delayed, consider waiting until 12 weeks postpartum.

Insertion after first-trimester abortion

Levosert can be inserted immediately after first trimester abortion. In this case no back-up contraception is needed.

Replacing Levosert

Levosert can be replaced by a new system at any time in the menstrual cycle. In this case no back-up contraception is needed.

Changing from another contraceptive method (e.g., combined hormonal contraceptives, implant)

- Levosert can be inserted immediately if it is reasonably certain that the woman is not pregnant.

- Need for back-up contraception: If it has been more than 7 days since menstrual bleeding began, the woman should abstain from vaginal intercourse or use additional contraceptive protection for the next 7 days.

Important information to consider during or after insertion

In case of difficult insertion and/or exceptional pain or bleeding during or after insertion, the possibility of perforation should be considered and appropriate steps should be taken, such as physical examination and ultrasound.

After insertion, women should be re-examined after 4 to 6 weeks to check the threads and ensure that the device is in the correct position. Physical examination alone (including checking of threads) may not be sufficient to exclude partial perforation, and ultrasound may be considered (see section 4.4).

Removal/replacement

Levosert is removed by gently pulling on the threads with forceps. If the threads are not visible and the system is found in the uterine cavity on ultrasound exam, it may be removed using a narrow forceps. This may require dilatation of the cervical canal or surgical intervention. After removal of Levosert, the system should be examined to ensure it is intact.

During difficult removals, single cases have been reported of the hormone cylinder sliding over the lateral arms and hiding them together inside the cylinder. This situation does not require further intervention once completeness of the IUS has been ascertained. The knobs of the lateral arms usually prevent complete detachment of the cylinder from the T-body.

Continuation of contraception after removal

• If the woman wishes to continue using the same method, a new system can be inserted immediately following removal of the original system.

• If the woman does not wish to continue using the same method but pregnancy is not desired, the removal should be carried out within 7 days of the onset of menstruation, provided the woman is experiencing regular menses. If the system is removed at some other time during the cycle or the woman does not experience regular menses and the woman has had intercourse within a week, she is at a risk of pregnancy. To ensure continuous contraception a barrier contraceptive method should be used (such as condoms) starting at least 7 days before the removal. After removal, the new contraceptive method should be started immediately (follow the instructions for use of the new contraceptive method).

Special populations

Paediatric population

Levosert has not been studied in patients below 16 years of age. Levosert should not be used before menarche.

Elderly

There is no indication for the use of Levosert in postmenopausal women.

Hepatic impairment

Levosert is contraindicated in patients with liver tumour or other acute or severe liver disease (see section 4.3).

Renal impairment

Levosert has not been studied in women with renal impairment.

Method of administration

To be inserted by a healthcare professional using aseptic technique.

Levosert is supplied in a sterile pack which should not be opened until required for insertion. Do not resterilise. For single use only. The exposed product should be handled with aseptic precautions. If the seal of the sterile package is broken, the product should be discarded (see section 6.6 for disposal instructions). Do not use if the inner package is damaged or open. Do not insert after the expiry date which is stated on the carton and the pouch after EXP. The expiry date refers to the last day of that month.

Levosert is supplied with a patient reminder card in the outer carton. Complete the patient reminder card and give it to the patient, after insertion.

Preparation for insertion

• Examine the patient to rule out contraindications for the insertion of Levosert (see section 4.3 and section 4.4 under Medical examination).

• Insert a speculum, visualize the cervix, and then thoroughly cleanse the cervix and vagina with a suitable antiseptic solution.

• Employ an assistant as necessary.

• Grasp the anterior lip of the cervix with a tenaculum or other forceps to stabilize the uterus. If the uterus is retroverted, it may be more appropriate to grasp the posterior lip of the cervix. Gentle traction on the forceps can be applied to straighten the cervical canal. The forceps should remain in position and gentle counter traction on the cervix should be maintained throughout the insertion procedure.

• Advance a uterine sound through the cervical canal to the fundus to measure the depth. If uterine depth is < 5.5 cm discontinue the procedure. Confirm the direction of the uterine cavity and to exclude any evidence of intrauterine abnormalities (e.g., septum, submucous fibroids) or a previously inserted intrauterine contraceptive which has not been removed. If difficulty is encountered, consider dilatation of the canal. If cervical dilatation is required, consider using analgesics and/or a paracervical block.

Levosert is inserted with the provided inserter into the uterine cavity by carefully following the insertion instructions provided in the box containing the Levosert IUS.

4.3. Contraindications

- Known or suspected pregnancy,

- Current or recurrent pelvic inflammatory disease;

- Lower genital tract infection;

- Postpartum endometritis;

- Infected abortion during the past three months;

- Cervicitis, cervical dysplasia;

- Suspected or confirmed uterine or cervical malignancy;

- Liver tumour or other acute or severe liver disease;

- Congenital or acquired abnormality of the uterus including fibroids if they distort the uterine cavity;

- Undiagnosed abnormal uterine bleeding;

- Conditions associated with increased susceptibility to infections;

- Current or suspected hormone dependent tumours such as breast cancer (see section 4.4);

- Acute malignancies affecting the blood or leukaemias except when in remission,

- Recent trophoblastic disease while hCG levels remain elevated;

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Medical examination

Before insertion, a complete personal and family medical history should be taken. Physical examination should be guided by this and by the contraindications and warnings for use. Pulse and blood pressure should be measured and a bimanual pelvic examination performed to establish the orientation of the uterus. Prior to insertion pregnancy should be excluded and genital infection should be successfully treated. Women should be advised that Levosert does not protect against HIV (AIDS) and other sexually transmitted disease (please refer to the section below on pelvic infections).

The patient should be re-examined 4 to 6 weeks after insertion to check the threads and ensure that the device is in the correct position. Vaginal ultrasound examination may be considered to ascertain the correct position of the system. In case Levosert cannot be located in the uterine cavity, expulsion or complete perforation should be considered (see paragraph “perforation” below) and X-ray may be used. Thereafter, re-examination should be performed once a year or more frequently if clinically indicated.

Women should be encouraged to attend cervical and breast screening as appropriate for their age.

Levosert is not for use as a post-coital contraceptive.

Conditions under which Levosert can be used with caution

Levosert may be used with caution after specialist consultation, or removal of the system should be considered, if any of the following conditions exist or arise for the first time during treatment:

- Migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia

- Unusually severe or unusually frequent headache

- Jaundice

- Marked increase of blood pressure

- Malignancies affecting the blood or leukaemias in remission

- Use of chronic corticosteroid therapy

- Past history of symptomatic functional ovarian cysts

- Active or previous severe arterial disease, such as stroke or myocardial infarction

- Severe or multiple risk factors for arterial disease

- Thrombotic arterial or any current embolic disease

- Acute venous thromboembolism.

Levosert may be used with caution in women who have congenital heart disease or valvular heart disease at risk of infective endocarditis.

Irregular bleedings may mask some symptoms and signs of endometrial polyps or cancer, and in these cases diagnostic measures have to be considered.

In general, women using Levosert should be encouraged to stop smoking.

Insertion / removal warnings and precautions

General information: Insertion and removal may be associated with some pain and bleeding. In case of difficult insertion and/or exceptional pain or bleeding during or after insertion, physical examination and ultrasound should be performed immediately to exclude perforation of the uterine corpus or cervix (see also 'Perforation').

The procedure may precipitate fainting as a vasovagal reaction or a seizure in an epileptic patient. In the event of early signs of a vasovagal attack, insertion may need to be abandoned or the system removed. The woman should be kept supine, the head lowered and the legs elevated to the vertical position if necessary in order to restore cerebral blood flow. A clear airway must be maintained; an airway should always be at hand. Persistent bradycardia may be controlled with intravenous atropine. If oxygen is available it may be administered.

Perforation: Perforation of the uterine corpus or cervix may occur, most commonly during insertion, although it may not be detected until sometime later. In some cases, the device may migrate to the intra-abdominal area. This may be associated with severe pain and continued bleeding. If perforation is suspected the system should be removed as soon as possible; surgery may be required.

The incidence of perforation during or following Levosert insertion in the clinical trial, which excluded breastfeeding women, was 0.1%.

In a large prospective comparative non-interventional cohort study in IUS/IUD users (N = 61,448 women), the incidence of perforation was 1.3 (95% CI: 1.1‑1.6) per 1,000 insertions in the entire study cohort; 1.4 (95% CI: 1.1‑1.8) per 1,000 insertions in the cohort for another LNG-IUS and 1.1 (95% CI: 0.7‑1.6) per 1,000 insertions in the copper IUD cohort.

The study showed that both breastfeeding at the time of insertion and insertion up to 36 weeks after giving birth were associated with an increased risk of perforation (see Table 2). These risk factors were independent of the type of IUS/IUD inserted.

Table 2: Incidence of perforation per 1,000 insertions for the entire study cohort, stratified by breastfeeding and time since delivery at insertion (parous women)

Breastfeeding at time of insertion

Not breastfeeding at time of insertion

Insertion ≤ 36 weeks after delivery

5.6

(95% CI 3.9-7.9; n=6,047 insertions)

1.7

(95% CI 0.8-3.1; n=5,927 insertions)

Insertion > 36 weeks after delivery

1.6

(95% CI 0.0-9.1; n=608 insertions)

0.7

(95% CI 0.5-1.1; n=41,910 insertions)

Breast‑feeding at the time of insertion and insertion up to 36 weeks after giving birth were confirmed as risk factors also in the subgroup that were followed up for 5 years.

The risk of perforation may be increased in post-partum insertions (see section 4.2), in lactating women and in women with a fixed retroverted uterus.

Re-examination after insertion should follow the guidance given above under the heading "Medical examination" including the consideration to use vaginal ultrasound examination to ascertain the correct position of the system 4 to 12 weeks thereafter, which may be adapted as clinically indicated in women with risk factors for perforation.

Pelvic infection: In users of copper intrauterine devices (IUDs), the highest rate of pelvic infections occurs during the first month after insertion and decreases later.

Known risk factors for pelvic inflammatory disease are multiple sexual partners, frequent intercourse and young age. Pelvic infection may have serious consequences as it may impair fertility and increase the risk of ectopic pregnancy. As with other gynaecological or surgical procedures, severe infection or sepsis (including group A streptococcal sepsis) can occur following IUS insertion, although this is extremely rare.

For women using Levosert with symptoms and signs suggestive of pelvic infection, bacteriological examinations are indicated and monitoring is recommended even with discrete symptoms, and appropriate antibiotics should be started. There is no need to remove Levosert unless the symptoms fail to resolve within the following 72 hours or unless the woman wishes Levosert to be removed. Levosert must be removed if the woman experiences recurrent endometritis or pelvic infection, or if an acute infection is severe.

Complications leading to failure

Expulsion: In clinical trials with Levosert in the indication contraception, the incidence of expulsion was low (<4% of insertions) and in the same range as reported for other IUDs and IUSs. Symptoms of partial or complete expulsion of Levosert may include bleeding or pain. However, a system can be expelled from the uterine cavity without the woman noticing it, leading to loss of contraceptive protection. As Levosert decreases menstrual flow, increase of menstrual flow may be indicative of an expulsion.

Risk of expulsion is increased in

• Women with history of heavy menstrual bleeding (including women who use Levosert for treatment of heavy menstrual bleeding)

• Women with greater than normal BMI at the time of insertion; this risk increases gradually with increasing BMI

Woman should be counselled on possible signs of expulsion and how to check the threads of Levosert and advised to contact a healthcare professional if the threads cannot be felt. A barrier contraceptive (such as a condom) should be used until the location of Levosert has been confirmed.

Partial expulsion may decrease the effectiveness of Levosert.

A partially expelled Levosert should be removed. A new system can be inserted at the time of removal, provided pregnancy has been excluded.

Lost threads: If the retrieval threads are not visible at the cervix on follow-up examination, first exclude pregnancy. The threads may have been drawn up into the uterus or cervical canal and may reappear during the next menstrual period. If they cannot be found, they may have broken off, the system may have been expelled, or rarely the device may be extra-uterine after having perforated the uterus. Vaginal ultrasound examination should be arranged to locate the device and alternative contraception should be advised in the meantime. If an ultrasound cannot locate the device and there is no evidence of expulsion, a plain abdominal X-ray should be performed to exclude an extra-uterine device.

Bleeding irregularities

Irregular bleeding: Levosert usually achieves a significant reduction in menstrual blood loss within 3 to 6 months of treatment. Increased menstrual flow or unexpected bleeding may be indicative of expulsion. If menorrhagia persists then the woman should be re-examined. An assessment of the uterine cavity should be performed using ultrasound scan. An endometrial biopsy should also be considered.

Risk in pre-menopausal women

Because irregular bleeding/spotting may occur during the first months of therapy in pre-menopausal women, it is recommended to exclude endometrial pathology before insertion of Levosert.

When to check for pregnancy in women of child bearing potential: The possibility of pregnancy should be considered if menstruation does not occur within six weeks of the onset of previous menstruation and expulsion should be excluded. A repeated pregnancy test is not necessary in amenorrhoeic subjects unless indicated by other symptoms. In women of fertile age, oligomenorrhoea and/or amenorrhoea develops gradually in about 20% of the users. For details of amenorrhoea rates, see section 5.1.

Treatment review advice for menorrhagia: Levosert usually achieves a significant reduction in menstrual blood loss within 3 to 6 months of treatment. If significant reduction in blood loss is not achieved in these time-frames, alternative treatments should be considered.

Other risks during use

Ectopic pregnancy: The absolute risk of ectopic pregnancy in users of levonorgestrel IUS is low. However, when a woman becomes pregnant with Levosert in situ, the relative likelihood of ectopic pregnancy is increased. The possibility of ectopic pregnancy should be considered in the case of lower abdominal pain - especially in connection with missed periods or if an amenorrhoeic woman starts bleeding.

In the conducted clinical study, the overall incidence of ectopic pregnancy with Levosert was approximately 0.12 per 100 woman-years. Women considering Levosert should be counselled on the signs, symptoms and risks of ectopic pregnancy. For women who become pregnant while using Levosert, the possibility of an ectopic pregnancy must be considered and evaluated.

Women with a previous history of ectopic pregnancy, tubal surgery or pelvic infection carry an increased risk of ectopic pregnancy. The risk of ectopic pregnancy in women who have a history of ectopic pregnancy and use Levosert is unknown. The possibility of ectopic pregnancy should be considered in the case of lower abdominal pain, especially in connection with missed periods or if an amenorrhoeic woman starts bleeding. Ectopic pregnancy may require surgery and may result in loss of fertility.

Ovarian cysts: Ovulatory cycles with follicular rupture usually occur in women of fertile age. Sometimes atresia of the follicle is delayed and folliculogenesis may continue. These enlarged follicles cannot be distinguished clinically from ovarian cysts. Most of these follicles are asymptomatic, although some may be accompanied by pelvic pain or dyspareunia.

In a clinical trial of Levosert that enrolled 280 women presenting with heavy menstrual bleeding of which 141 received Levosert, ovarian cyst (symptomatic and asymptomatic) was reported in 9.9% patients within 12 months of insertion. In a clinical trial of Levosert which enrolled 1,751 subjects, symptomatic ovarian cysts occurred in approximately 4.5% of subjects using Levosert, and 0.3 % of subjects discontinued use of Levosert because of an ovarian cyst.

In most cases, the ovarian cysts disappear spontaneously during two to three months observation. Should this not happen, continued ultrasound monitoring and other diagnostic/therapeutic measures are recommended. Rarely, surgical intervention may be required.

Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.

Breast cancer:

Risk in pre-menopausal women

A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using combined oral contraceptives (COCs), mainly using oestrogen-progestogen preparations. The excess risk gradually disappears during the course of the 10 years after cessation of COC use. Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. The risk of having breast cancer diagnosed in users of progestogen-only methods (POPs, implants and injectables), including Levosert, is possibly of similar magnitude to that associated with COC. A number of observational studies have investigated the risk of being diagnosed with breast cancer in levonorgestrel IUS users, mostly in comparison with the risk in individuals who did not use hormonal contraceptives or in those who did not use LNG-IUS. While some of these studies have suggested a slightly increased relative risk in levonorgestrel IUS users, others have not, and the available evidence is overall less conclusive than for COCs.

General information

Glucose tolerance: Low-dose levonorgestrel may affect glucose tolerance and blood glucose concentrations should be monitored in diabetic users of Levosert.

The T-frame of Levosert contains barium sulphate so that it can be seen on X-rays.

4.5. Interaction with other medicinal products and other forms of interaction

The metabolism of progestagens may be increased by concomitant use of substances known to induce drug-metabolizing enzymes, specifically cytochrome P450 enzymes, such as anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine) and anti-infectives (e.g. griseofulvin, fluconazole, rifampicin, rifabutin, nevirapine, efavirenz). On the other hand, substances known to inhibit drug-metabolizing enzymes (e.g. itraconazole, ketoconazole) may increase serum concentrations of levonorgestrel. The influence of these drugs on the contraceptive efficacy of Levosert is not known, but it is not believed to be of major importance due to the local mechanism of action.

4.6. Fertility, pregnancy and lactation

Pregnancy

Levosert is contraindicated during an existing or suspected pregnancy (see section 4.3). In case of an accidental pregnancy with Levosert in situ (see section 5.1), ectopic pregnancy should be excluded (see section 4.4) and the system should be removed as soon as possible, as there is a high risk for pregnancy complications (abortion, preterm labour, infection and sepsis). Removal of Levosert or probing of the uterus may also result in spontaneous abortion. Should these procedures not be possible or if the woman wishes to continue the pregnancy, the woman should be informed about these risks, and accordingly, such pregnancies should be closely monitored. The woman should be instructed to report all symptoms that suggest complications of the pregnancy, like cramping abdominal pain with fever.

Local exposure to levonorgestrel:

In addition, an increased risk of virilising effects in a female foetus because of the intrauterine exposure to levonorgestrel cannot be excluded. There have been isolated cases of masculinisation of the external genitalia of the female foetus following local exposure to levonorgestrel during pregnancy with an LNG-IUS in place.

Breastfeeding

Levonorgestrel is excreted in very small quantities in breast milk after use in levonorgestrel IUS. Since no risk for the child is expected, breast feeding can be continued during use of Levosert. Uterine bleeding has rarely been reported in women using a levonorgestrel IUS during lactation.

Fertility

The use of levonorgestrel IUS does not alter the course of female fertility after removal of the IUS.

4.7. Effects on ability to drive and use machines

Levosert has no known influence on the ability to drive or use machines.

4.8. Undesirable effects

Undesirable effects are more common during the first months after the insertion, and subside during prolonged use.

Very common undesirable effects (occurring in more than 10% of users) include uterine/vaginal bleeding including spotting, oligomenorrhoea, amenorrhoea (see section 5.1) and benign ovarian cysts.

The frequency of benign ovarian cysts depends on the diagnostic method used, and in clinical trials enlarged follicles have been diagnosed in 12% of the subjects using a levonorgestrel IUS. Most of the follicles are asymptomatic and disappear within three months.

The table below reports adverse reactions by MedDRA system organ class (MedDRA SOCs). The frequencies are based on clinical trial data.

System organ class

Undesirable effects

Very common:

≥ 1/10

Common:

≥ 1/100 to < 1/10

Uncommon:

≥ 1/1,000 to < 1/100

Rare:

≥ 1/10,000 to < 1/1,000

Infections and infestations

Vaginal bacterial infections, Vulvovaginal mycotic infections

Immune system disorders

Hypersensitivity including rash, urticaria and angioedema

Psychiatric disorders

Depressive mood

Nervousness

Decreased libido

Nervous system disorders

Headache

Migraine

Presyncope

Syncope

Vascular disorders

Dizziness

Gastrointestinal disorders

Abdominal pain/discomfort

Nausea

Abdominal distension

Vomiting

Skin and subcutaneous tissue disorders

Acne

Alopecia

Hirsutism

Pruritus

Eczema

Chloasma/skin hyperpigmentation

Rash

Urticaria

Musculoskeletal and connective tissue disorders

Back pain

Pregnancy, puerperium and perinatal conditions

Ectopic pregnancy

Reproductive system and breast disorders

Uterine/vaginal bleeding including spotting, oligomenorrhea, amenorrhea

Benign ovarian cysts

Pelvic pain

Dysmenorrhoea

Vaginal discharge

Vulvovaginitis

Breast tenderness

Breast pain

Dyspareunia

Uterine spasm

Uterine perforation*

Pelvic inflammatory disease

Endometritis

Cervicitis

Papanicolaou smear normal, class II

General disorders and administration site conditions

Procedural pain

Procedural bleeding

Intrauterine contraceptive device expelled

Oedema

Investigations

Weight increased

*This frequency is based on a large prospective comparative non-interventional cohort study in IUS/IUD users, which showed that breast feeding at the time of insertion and insertion up to 36 weeks after giving birth are independent risk factors for perforation (see section 4.4). In clinical trials with levonorgestrel IUS that excluded breast-feeding women the frequency of perforation was "rare".

Infections and infestations

Cases of sepsis (including group A streptococcal sepsis) have been reported following IUS insertion (see section 4.4)

Pregnancy, puerperium and perinatal conditions

When a woman becomes pregnant with Levosert in situ, the relative risk of ectopic pregnancy is increased (see sections 4.4 and 4.6).

Reproductive system and breast disorders

Cases of breast cancer have been reported in levonorgestrel IUS users (frequency not known, see section 4.4).

The following adverse reactions have been reported in connection with the insertion or removal procedure of Levosert: pain, bleeding, and insertion-related vasovagal reaction with dizziness or syncope (see section 4.4). The procedure may also precipitate a seizure in patients with epilepsy.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the MHRA Yellow Card Scheme (www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Not applicable.

💬 Ask about this leaflet

Ask anything about Levosert 20 microgram/24 hours Intrauterine Delivery System. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →